Despite Shenyang Xingqi Pharmaceutical Ltd's weak recent revenue performance, the high P/S ratio points to investors holding stocks, anticipating significant revenue recovery. But with forecasted growth mirrored by the industry, the current ratio may not be sustainable without improved performance.